The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
90
Acpru /Id# 282128
Grayslake, Illinois, United States
RECRUITINGNumber of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Time frame: Up to Approximately Day 211
Maximum Observed Plasma Concentration (Cmax) of ABBV-1451
Cmax of ABBV-1451.
Time frame: Up to Approximately Day 211
Time to Cmax (Tmax) of ABBV-1451
Tmax of ABBV-1451.
Time frame: Up to Approximately Day 211
Terminal Phase Elimination Rate Constant (β) of ABBV-1451
β of ABBV-1451.
Time frame: Up to Approximately Day 211
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1451
t1/2 of ABBV-1451.
Time frame: Up to Approximately Day 211
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-1451
AUCt of ABBV-1451.
Time frame: Up to Approximately Day 211
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-1451
AUCinf of ABBV-1451.
Time frame: Up to Approximately Day 211
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Infusion